Lung Cancer Surgery Market - Global Forecast 2025-2032

The lung cancer surgery market is undergoing profound transformation, driven by a fusion of technological innovation, evolving clinical best practices, and new stakeholder demands. Senior executives face an increasingly complex yet promising environment as precise, minimally invasive solutions become central to thoracic oncology care.

Market Snapshot: Lung Cancer Surgery Market Size and Growth

The lung cancer surgery market grew from USD 6.01 billion in 2024 to USD 6.38 billion in 2025. With a projected CAGR of 6.10%, revenues are expected to reach USD 9.66 billion by 2032. Expanding adoption of minimally invasive and robotic-assisted approaches, combined with ongoing clinical standardization and supply chain adjustments, are shaping a market that prioritizes both operational efficiency and patient outcomes.

Lung Cancer Surgery Market Scope & Segmentation

This report provides a comprehensive view of the lung cancer surgery landscape with segmentation by approach, product, cancer type, end user, geographic region, and key company profiles to allow targeted benchmarking and opportunity analysis:

• Approach: Includes minimally invasive procedures such as robotic-assisted thoracic surgery (Da Vinci systems) and video-assisted thoracoscopic surgery (multiportal, uniportal), as well as open surgery options.
• Product Type: Covers access devices and trocars, endoscopes and visualization systems, a spectrum of energy devices (advanced bipolar, electrosurgical, ultrasonic), and stapling devices (manual and powered staplers).
• Cancer Type: Addresses non-small cell lung cancer (with subtypes including adenocarcinoma, large cell carcinoma, squamous cell carcinoma) and small cell lung cancer.
• End User: Profiles hospitals and ambulatory surgical centers, reflecting differing procurement needs and workflow priorities.
• Region: Analyzes developments in the Americas (with focus on United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, UAE, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (covering China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Companies: Evaluates initiatives and trends from leading players such as Intuitive Surgical, Medtronic, Johnson & Johnson, Stryker, Olympus, KARL STORZ, Becton Dickinson, Boston Scientific, Smith & Nephew, and Zimmer Biomet.

Key Takeaways for Decision-Makers

• Adoption of minimally invasive and robotic techniques is accelerating, with precision medicine driving customized surgical protocols and improved recovery timelines.
• Technological integration, such as AI-guided intraoperative imaging and advanced bipolar and ultrasonic devices, continues to reshape surgical workflows and resource allocation.
• Regulatory changes and tariff adjustments in the United States are prompting strategic reviews of global supply chains, including localization of manufacturing and renegotiation of vendor contracts.
• Procurement patterns differ between hospitals and ambulatory centers, fostering innovation in streamlined equipment and workflow solutions tailored to care setting.
• Market competition is intensifying, with leaders consolidating through M&A and forming partnerships to gain rapid access to digital health capabilities and next-generation devices.
• Regional disparities in infrastructure and purchasing priorities influence technology diffusion rates and dictate varying strategic approaches for market entry and expansion.

Tariff Impact: Strategic Supply Chain Responses

2025 U.S. tariff adjustments have significantly impacted lung cancer surgical device supply chains and cost management. Device manufacturers are relocating key manufacturing closer to end-user markets, diversifying sourcing, and engaging in partnerships with regional assemblers to offset cost increases. Hospitals and surgery centers are pursuing collective procurement and contract renegotiation, supporting continued access to precision devices while minimizing cost escalation and lead-time risks.

Methodology & Data Sources

The report utilizes a blended research framework combining primary interviews with thoracic surgeons and procurement leaders, detailed analysis of procurement data, and validation via secondary sources including regulatory filings and market literature. Analytical techniques include qualitative thematic coding, comparative product assessment, and sensitivity analysis for regulatory and technology-driven disruptions.

Why This Report Matters

• Enables executive teams to assess competitor strategies and technology adoption rates in the lung cancer surgery market.
• Delivers actionable insights for procurement, investment, and innovation planning across diverse global regions.
• Supports evidence-based decisions by aligning supply chain adjustments and reimbursement initiatives with current regulatory dynamics.

Conclusion

As lung cancer surgery advances through digital, procedural, and regulatory transformation, senior decision-makers must leverage integrated strategies to optimize operational and clinical results. This research enables clear alignment of resources with market trends, positioning industry leaders to confidently address ongoing change.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.